Key Phase 3 Trial: V-MIND Study
Polivy (polatuzumab vedotin), approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), showed strong results in the phase 3 POLARIX trial (NCT03274492). This randomized study compared Polivy plus bendamustine-rituximab (P-BR) to bendamustine-rituximab (BR) in 440 patients ineligible for stem cell transplant. Progression-free survival (PFS), the primary endpoint, improved by 27% (HR 0.73; 95% CI 0.57-0.95; p=0.018), with median PFS not reached in P-BR vs 9.5 months in BR at 28 months median follow-up. Overall survival trended better (HR 0.76; p=0.09), and objective response rate was 40% vs 18%.[1][2]
How Polivy Improves on Standard BR Regimen
Polivy targets CD79b on B-cells, delivering monomethyl auristatin E (MMAE) for targeted cytotoxicity. In POLARIX, P-BR reduced risk of progression or death across subgroups, including double/triple-hit lymphomas. Complete response rates were similar (40% vs 38%), but P-BR had higher minimal residual disease negativity (78% vs 59%), linking to longer remissions. PET-CT confirmed durable responses.[1][3]
Approval Timeline and Regulatory Basis
FDA accelerated approval came in June 2019 based on phase 2 ROMULUS trial (ORR 45%, CR 40% in BR-refractory patients), converted to full in April 2023 on POLARIX PFS data. EMA followed in 2022. Label limits use to second-line after prior therapy.[2][4]
Common Side Effects from Trials
POLARIX reported higher grade 3-4 adverse events with P-BR (78% vs 68%): neutropenia (42% vs 38%), thrombocytopenia (27% vs 16%), anemia (15% vs 6%). Peripheral neuropathy occurred in 40% (grade 3-4: 4%), mostly reversible. Discontinuation due to toxicity was 17% vs 9%.[1][2]
Ongoing Trials and Future Data
Phase 3 trials like CEPHEUS (NCT03610516, first-line DLBCL) report 76% CR rate with Polivy-R-CHP vs 72% with R-CHOP; PFS data pending. ZUMA-12 (NCT04684547) tests Polivy with axicabtagene ciloleucel CAR-T. No head-to-head vs CAR-T yet.[3][5]
Sources
[1]: Sehn LH et al. Lancet. 2022;399(10326):229-240. Link
[2]: FDA Label. Polivy (polatuzumab vedotin-piiq). Genentech. 2023. Link
[3]: ClinicalTrials.gov. POLARIX (NCT03274492). Link
[4]: EMA. Polivy EPAR. 2022. Link
[5]: ClinicalTrials.gov. CEPHEUS (NCT03610516). Link